With key EHA data coming up, Shattuck Labs looks to build on its hypothesis that adding an immune agonism component will transform the SIRPα space
Co-Founder and CEO Taylor Schreiber describes the bi-specific fusion protein construct he is co-inventor of and why he believes it is needed to succeed in the SIRPα (CD47) approach to oncology.